Ascletis Launches Phase I Trials for Two Obesity Treatments in U.S.
Event summary
- Ascletis initiated Phase I trials for ASC36, a once-monthly to once-quarterly amylin receptor peptide agonist, and ASC36_35FDC, a co-formulation targeting amylin, GLP-1R, and GIPR receptors.
- Both trials are randomized, double-blind, placebo-controlled studies evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in obese or overweight participants with weight-related comorbidities.
- ASC36_35FDC demonstrated 51% greater relative body weight reduction compared to eloralintide and tirzepatide combination in preclinical studies.
- The trials follow FDA clearance of Investigational New Drug (IND) applications for both ASC36 and ASC36_35FDC.
The big picture
Ascletis is expanding its obesity pipeline with potentially first-in-class treatments, leveraging proprietary technologies to extend drug half-life and reduce injection frequency. The Phase I trials mark a strategic push into the competitive weight-loss market, where differentiated delivery mechanisms could drive adoption. Success hinges on demonstrating superior efficacy and safety profiles compared to existing therapies.
What we're watching
- Clinical Efficacy
- Whether ASC36 and ASC36_35FDC can replicate preclinical weight loss results in human trials.
- Regulatory Pathway
- The pace at which Ascletis advances these candidates through Phase I to potential approval.
- Market Differentiation
- How Ascletis positions its once-monthly formulations against competitors like Eli Lilly's weekly injections.
Related topics